What was the overall market valuation of the Germany remdesivir market in 2024?

The overall market valuation was $397.5 Million in 2024. Read More

What is the projected market valuation for the Germany remdesivir market by 2035?

The projected valuation for 2035 is $832.6 Million. Read More

What is the expected CAGR for the Germany remdesivir market during the forecast period 2025 - 2035?

The expected CAGR during the forecast period 2025 - 2035 is 6.95%. Read More

What are the market segments for remdesivir in Germany?

The market segments include Dosage and Distribution Channel. Read More

What was the valuation of the 5mg dosage segment in 2024?

The valuation of the 5mg dosage segment was $79.5 Million in 2024. Read More

What is the projected valuation for the 10mg dosage segment by 2035?

The projected valuation for the 10mg dosage segment by 2035 is $249.3 Million. Read More

How much revenue did hospitals generate from remdesivir in 2024?

Hospitals generated $200.0 Million in revenue from remdesivir in 2024. Read More

What is the expected revenue from drug stores for remdesivir by 2035?

The expected revenue from drug stores for remdesivir by 2035 is $300.0 Million. Read More

What was the valuation of the 'Others' distribution channel segment in 2024?

The valuation of the 'Others' distribution channel segment was $47.5 Million in 2024. Read More

Germany Remdesivir Market

Q: Which companies are the key players in the Germany remdesivir market?

Key players include Gilead Sciences, Cipla, Hetero Labs, Mylan, Fujifilm Toyama Chemical, Janssen Pharmaceuticals, Bristol-Myers Squibb, and Aurobindo Pharma. Read More

ID: MRFR/HC/50052-HCR

200 Pages

Rahul Gotadki

Last Updated: February 06, 2026

Germany Remdesivir Market Research Report By Dosage (5mg, 10mg, 50mg, 100mg) and By Distribution Channel (Hospitals, Drug stores) - Growth & Industry Forecast 2025 To 2035

Germany Remdesivir Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)6.95%

2024 Market Size$ 397.5 Million

2025 Market Size$ 425.13 Million

2035 Market Size$ 832.6 Million

Key Players

Gilead Sciences

Cipla

Hetero Labs

Mylan

Fujifilm Toyama Chemical

Janssen Pharmaceuticals

Trends

Regulatory Framework Enhancements
Focus on Personalized Medicine
Collaboration Between Sectors

Opportunities

Emerging Trends in Telemedicine
Increasing Healthcare Expenditure
Investment in Research and Development

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Dosage (USD Million)
  1. 4.1.1 5mg
  2. 4.1.2 10mg
  3. 4.1.3 50mg
  4. 4.1.4 100mg
2. 4.2 Healthcare, BY Distribution Channel (USD Million)
  1. 4.2.1 Hospitals
  2. 4.2.2 Drug stores
  3. 4.2.3 Others
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Gilead Sciences (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Cipla (IN)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Hetero Labs (IN)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Mylan (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Fujifilm Toyama Chemical (JP)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Janssen Pharmaceuticals (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Bristol-Myers Squibb (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Aurobindo Pharma (IN)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 GERMANY MARKET ANALYSIS BY DOSAGE
3. 6.3 GERMANY MARKET ANALYSIS BY DISTRIBUTION CHANNEL
4. 6.4 KEY BUYING CRITERIA OF HEALTHCARE
5. 6.5 RESEARCH PROCESS OF MRFR
6. 6.6 DRO ANALYSIS OF HEALTHCARE
7. 6.7 DRIVERS IMPACT ANALYSIS: HEALTHCARE
8. 6.8 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
9. 6.9 SUPPLY / VALUE CHAIN: HEALTHCARE
10. 6.10 HEALTHCARE, BY DOSAGE, 2024 (% SHARE)
11. 6.11 HEALTHCARE, BY DOSAGE, 2024 TO 2035 (USD Million)
12. 6.12 HEALTHCARE, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
13. 6.13 HEALTHCARE, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
14. 6.14 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY DOSAGE, 2025-2035 (USD Million)
  2. 7.2.2 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

Germany Germany Remdesivir Market Segmentation

Germany Remdesivir Market By Dosage (USD Million, 2025-2035)

5mg
10mg
50mg
100mg

Germany Remdesivir Market By Distribution Channel (USD Million, 2025-2035)

Hospitals
Drug stores
Others

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”